Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tourette Syndrome | 9 | 2019 | 25 | 2.830 |
Why?
|
| Movement Disorders | 6 | 2020 | 118 | 1.860 |
Why?
|
| Parkinson Disease | 19 | 2023 | 1069 | 1.750 |
Why?
|
| Tic Disorders | 7 | 2017 | 11 | 1.640 |
Why?
|
| Estrogens | 5 | 2003 | 36 | 0.810 |
Why?
|
| Conversion Disorder | 1 | 2020 | 5 | 0.740 |
Why?
|
| Neurological Rehabilitation | 1 | 2020 | 7 | 0.740 |
Why?
|
| Anxiety | 1 | 2020 | 156 | 0.660 |
Why?
|
| Tremor | 1 | 2020 | 141 | 0.650 |
Why?
|
| Antipsychotic Agents | 3 | 2010 | 68 | 0.640 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2020 | 144 | 0.630 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2019 | 23 | 0.580 |
Why?
|
| Depression | 2 | 2020 | 481 | 0.580 |
Why?
|
| Humans | 43 | 2023 | 30999 | 0.570 |
Why?
|
| Antiparkinson Agents | 5 | 2004 | 98 | 0.550 |
Why?
|
| Somatoform Disorders | 2 | 2013 | 20 | 0.540 |
Why?
|
| Female | 29 | 2023 | 16985 | 0.520 |
Why?
|
| Male | 27 | 2023 | 16447 | 0.520 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2019 | 35 | 0.500 |
Why?
|
| Parents | 1 | 2016 | 110 | 0.500 |
Why?
|
| Nervous System Diseases | 1 | 2017 | 155 | 0.500 |
Why?
|
| Hospitalization | 1 | 2017 | 337 | 0.470 |
Why?
|
| Psychotherapy, Psychodynamic | 1 | 2013 | 3 | 0.450 |
Why?
|
| Psychotherapy, Brief | 1 | 2013 | 4 | 0.450 |
Why?
|
| Severity of Illness Index | 7 | 2020 | 1133 | 0.450 |
Why?
|
| Placebo Effect | 1 | 2013 | 24 | 0.420 |
Why?
|
| Child | 8 | 2017 | 1430 | 0.420 |
Why?
|
| Psychophysiologic Disorders | 1 | 2012 | 9 | 0.400 |
Why?
|
| Supranuclear Palsy, Progressive | 3 | 2006 | 38 | 0.390 |
Why?
|
| Tics | 2 | 2001 | 7 | 0.380 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 360 | 0.370 |
Why?
|
| Middle Aged | 16 | 2020 | 10197 | 0.360 |
Why?
|
| Adolescent | 9 | 2017 | 2401 | 0.340 |
Why?
|
| Body Weight | 1 | 2010 | 141 | 0.340 |
Why?
|
| Complementary Therapies | 1 | 2009 | 10 | 0.340 |
Why?
|
| Cerebral Cortex | 3 | 2004 | 195 | 0.340 |
Why?
|
| Adult | 12 | 2020 | 8933 | 0.330 |
Why?
|
| Sialorrhea | 2 | 2009 | 5 | 0.320 |
Why?
|
| Indans | 1 | 2008 | 10 | 0.300 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2008 | 15 | 0.300 |
Why?
|
| Piperidines | 1 | 2008 | 33 | 0.300 |
Why?
|
| Young Adult | 4 | 2020 | 2063 | 0.300 |
Why?
|
| Adrenal Medulla | 1 | 2007 | 15 | 0.290 |
Why?
|
| Neurodegenerative Diseases | 2 | 2000 | 119 | 0.290 |
Why?
|
| Inpatients | 2 | 2020 | 150 | 0.290 |
Why?
|
| Brain | 5 | 2011 | 1801 | 0.290 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 198 | 0.280 |
Why?
|
| Estradiol | 2 | 2004 | 46 | 0.280 |
Why?
|
| Aged | 16 | 2020 | 10047 | 0.260 |
Why?
|
| Neurologic Examination | 3 | 2001 | 138 | 0.250 |
Why?
|
| Dopamine | 4 | 2006 | 149 | 0.240 |
Why?
|
| Progesterone | 2 | 2001 | 21 | 0.240 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2014 | 442 | 0.240 |
Why?
|
| Cholinergic Fibers | 1 | 2004 | 8 | 0.230 |
Why?
|
| Prosencephalon | 1 | 2004 | 9 | 0.230 |
Why?
|
| Sex Factors | 2 | 2023 | 511 | 0.230 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 21 | 0.230 |
Why?
|
| Menstrual Cycle | 2 | 2001 | 31 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2006 | 190 | 0.220 |
Why?
|
| Educational Status | 2 | 2017 | 312 | 0.220 |
Why?
|
| Cross-Over Studies | 2 | 2013 | 72 | 0.220 |
Why?
|
| Aging | 3 | 2004 | 1727 | 0.220 |
Why?
|
| Levodopa | 2 | 2004 | 80 | 0.210 |
Why?
|
| Thiazoles | 1 | 2002 | 31 | 0.200 |
Why?
|
| Sex Characteristics | 1 | 2023 | 144 | 0.190 |
Why?
|
| Tyrosine 3-Monooxygenase | 3 | 2007 | 84 | 0.190 |
Why?
|
| Hypoxia, Brain | 1 | 2001 | 11 | 0.190 |
Why?
|
| Myoclonus | 1 | 2001 | 24 | 0.180 |
Why?
|
| Sensory Aids | 1 | 2000 | 2 | 0.180 |
Why?
|
| Double-Blind Method | 4 | 2014 | 499 | 0.170 |
Why?
|
| Apomorphine | 1 | 2000 | 22 | 0.170 |
Why?
|
| Basal Ganglia Diseases | 1 | 2000 | 8 | 0.170 |
Why?
|
| Muscle Rigidity | 1 | 2000 | 26 | 0.170 |
Why?
|
| Speech | 1 | 2000 | 28 | 0.170 |
Why?
|
| Cues | 1 | 2000 | 60 | 0.170 |
Why?
|
| Kuru | 1 | 1999 | 1 | 0.170 |
Why?
|
| Ubiquinone | 2 | 2014 | 4 | 0.170 |
Why?
|
| Mood Disorders | 1 | 2019 | 32 | 0.170 |
Why?
|
| Child, Preschool | 3 | 2010 | 689 | 0.170 |
Why?
|
| Animals | 6 | 2012 | 4722 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 1999 | 59 | 0.160 |
Why?
|
| Antioxidants | 2 | 2014 | 65 | 0.160 |
Why?
|
| Polypharmacy | 1 | 1998 | 9 | 0.160 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 1504 | 0.160 |
Why?
|
| Hyperkinesis | 1 | 1998 | 9 | 0.150 |
Why?
|
| Cameroon | 1 | 2017 | 2 | 0.150 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1923 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2017 | 13 | 0.150 |
Why?
|
| Academic Performance | 1 | 2017 | 4 | 0.150 |
Why?
|
| Brain Diseases | 1 | 1998 | 82 | 0.150 |
Why?
|
| Walking | 1 | 2000 | 259 | 0.150 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 36 | 0.150 |
Why?
|
| Morbidity | 1 | 2017 | 64 | 0.150 |
Why?
|
| Myocardial Ischemia | 1 | 2017 | 49 | 0.140 |
Why?
|
| Ataxia | 1 | 1997 | 79 | 0.140 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 341 | 0.140 |
Why?
|
| Registries | 1 | 2017 | 201 | 0.130 |
Why?
|
| Time Factors | 2 | 2013 | 1672 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2017 | 333 | 0.120 |
Why?
|
| Comorbidity | 2 | 2008 | 507 | 0.120 |
Why?
|
| Age Factors | 1 | 2017 | 873 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2006 | 172 | 0.110 |
Why?
|
| Databases, Bibliographic | 1 | 2013 | 12 | 0.110 |
Why?
|
| Ovariectomy | 2 | 2004 | 27 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2006 | 275 | 0.100 |
Why?
|
| Autopsy | 2 | 2007 | 351 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2014 | 3807 | 0.100 |
Why?
|
| Dystonic Disorders | 1 | 2012 | 28 | 0.100 |
Why?
|
| Neurons | 2 | 2006 | 378 | 0.090 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 55 | 0.090 |
Why?
|
| HIV Infections | 1 | 2017 | 890 | 0.090 |
Why?
|
| Cognition Disorders | 1 | 1997 | 1055 | 0.090 |
Why?
|
| Dopamine Agents | 2 | 2000 | 27 | 0.090 |
Why?
|
| Primary Dysautonomias | 1 | 2009 | 6 | 0.080 |
Why?
|
| Cholinergic Antagonists | 2 | 2000 | 12 | 0.080 |
Why?
|
| Basal Ganglia | 2 | 1999 | 23 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2006 | 1211 | 0.080 |
Why?
|
| Salivary Glands | 1 | 2007 | 4 | 0.080 |
Why?
|
| Videotape Recording | 2 | 1998 | 38 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2010 | 452 | 0.070 |
Why?
|
| Chromogranin A | 1 | 2007 | 12 | 0.070 |
Why?
|
| Cell Survival | 1 | 2007 | 164 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2014 | 1898 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2007 | 175 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2008 | 429 | 0.070 |
Why?
|
| Head | 1 | 2006 | 27 | 0.070 |
Why?
|
| Awareness | 1 | 2006 | 41 | 0.060 |
Why?
|
| Multiple System Atrophy | 1 | 2006 | 44 | 0.060 |
Why?
|
| Substantia Nigra | 2 | 2006 | 145 | 0.060 |
Why?
|
| Myositis | 1 | 2006 | 41 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 161 | 0.060 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2004 | 16 | 0.060 |
Why?
|
| Reference Values | 2 | 2006 | 229 | 0.060 |
Why?
|
| Macaca mulatta | 1 | 2004 | 69 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2004 | 14 | 0.060 |
Why?
|
| Dyskinesias | 1 | 2004 | 34 | 0.060 |
Why?
|
| Dopamine Agonists | 1 | 2004 | 39 | 0.060 |
Why?
|
| Risk Factors | 1 | 2010 | 2588 | 0.060 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2003 | 16 | 0.050 |
Why?
|
| Aspartic Acid | 1 | 2003 | 15 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2003 | 45 | 0.050 |
Why?
|
| Education | 1 | 2002 | 41 | 0.050 |
Why?
|
| Synaptic Transmission | 2 | 2002 | 45 | 0.050 |
Why?
|
| Biological Availability | 1 | 2002 | 25 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2006 | 1311 | 0.050 |
Why?
|
| Carbidopa | 1 | 2002 | 20 | 0.050 |
Why?
|
| Benzothiazoles | 1 | 2002 | 16 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 61 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2002 | 70 | 0.050 |
Why?
|
| Postmenopause | 1 | 2002 | 62 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2002 | 113 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 144 | 0.050 |
Why?
|
| Drug Implants | 1 | 2001 | 11 | 0.050 |
Why?
|
| Disabled Persons | 1 | 2002 | 135 | 0.050 |
Why?
|
| Disease Progression | 2 | 2002 | 830 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2006 | 2042 | 0.040 |
Why?
|
| Larynx | 1 | 2000 | 15 | 0.040 |
Why?
|
| Heart Arrest | 1 | 2001 | 54 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2006 | 5189 | 0.040 |
Why?
|
| New Guinea | 1 | 1999 | 1 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2000 | 58 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2001 | 468 | 0.040 |
Why?
|
| Video Recording | 1 | 1999 | 44 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2000 | 100 | 0.040 |
Why?
|
| Forecasting | 1 | 1999 | 114 | 0.040 |
Why?
|
| Anticonvulsants | 1 | 2000 | 112 | 0.040 |
Why?
|
| Neck Muscles | 1 | 1998 | 12 | 0.040 |
Why?
|
| Peripheral Nerve Injuries | 1 | 1998 | 18 | 0.040 |
Why?
|
| Methysergide | 1 | 1998 | 3 | 0.040 |
Why?
|
| 5-Hydroxytryptophan | 1 | 1998 | 7 | 0.040 |
Why?
|
| Serotonin Antagonists | 1 | 1998 | 14 | 0.040 |
Why?
|
| London | 1 | 1998 | 3 | 0.040 |
Why?
|
| Rats | 1 | 2001 | 873 | 0.040 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 1998 | 22 | 0.040 |
Why?
|
| Dystonia | 1 | 1998 | 40 | 0.040 |
Why?
|
| Akathisia, Drug-Induced | 1 | 1998 | 2 | 0.040 |
Why?
|
| Stereotypic Movement Disorder | 1 | 1998 | 3 | 0.040 |
Why?
|
| Antisocial Personality Disorder | 1 | 1998 | 8 | 0.040 |
Why?
|
| Psychomotor Agitation | 1 | 1998 | 14 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2000 | 583 | 0.040 |
Why?
|
| Diagnostic Errors | 1 | 1998 | 39 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2000 | 330 | 0.040 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1997 | 2 | 0.040 |
Why?
|
| Prion Diseases | 1 | 1997 | 2 | 0.040 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1998 | 36 | 0.040 |
Why?
|
| Treatment Failure | 1 | 1998 | 167 | 0.040 |
Why?
|
| Prevalence | 1 | 1999 | 499 | 0.040 |
Why?
|
| Vasculitis | 1 | 1997 | 31 | 0.040 |
Why?
|
| Quality of Life | 1 | 2002 | 698 | 0.040 |
Why?
|
| Atrophy | 1 | 1997 | 100 | 0.040 |
Why?
|
| Lymphoma | 1 | 1997 | 46 | 0.040 |
Why?
|
| Referral and Consultation | 1 | 1998 | 91 | 0.040 |
Why?
|
| Shoulder Injuries | 1 | 1998 | 143 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2013 | 662 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 1997 | 128 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 1997 | 133 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 407 | 0.030 |
Why?
|
| Astrocytes | 1 | 1997 | 127 | 0.030 |
Why?
|
| Patient Care Team | 1 | 1998 | 152 | 0.030 |
Why?
|
| Gait | 1 | 2000 | 407 | 0.030 |
Why?
|
| Cross-Sectional Studies | 2 | 2013 | 1009 | 0.030 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 2 | 2006 | 14 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 69 | 0.030 |
Why?
|
| Alzheimer Disease | 1 | 2006 | 2132 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2006 | 430 | 0.030 |
Why?
|
| Spain | 1 | 2013 | 12 | 0.030 |
Why?
|
| United States | 1 | 1998 | 2375 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 1999 | 3659 | 0.020 |
Why?
|
| PubMed | 1 | 2009 | 13 | 0.020 |
Why?
|
| Constipation | 1 | 2009 | 24 | 0.020 |
Why?
|
| Deglutition Disorders | 1 | 2009 | 45 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 818 | 0.020 |
Why?
|
| Major Histocompatibility Complex | 1 | 2006 | 14 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 40 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 22 | 0.020 |
Why?
|
| Electromyography | 1 | 2006 | 78 | 0.020 |
Why?
|
| Cell Count | 1 | 2006 | 98 | 0.020 |
Why?
|
| Biopsy | 1 | 2006 | 249 | 0.020 |
Why?
|
| Neurofibrillary Tangles | 1 | 2006 | 199 | 0.020 |
Why?
|
| alpha-Synuclein | 1 | 2006 | 145 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2004 | 120 | 0.010 |
Why?
|
| Macaca fascicularis | 1 | 2003 | 26 | 0.010 |
Why?
|
| Coenzymes | 1 | 2002 | 1 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2006 | 370 | 0.010 |
Why?
|
| Cytoprotection | 1 | 2002 | 9 | 0.010 |
Why?
|
| Models, Animal | 1 | 2003 | 130 | 0.010 |
Why?
|
| Motor Skills | 1 | 2003 | 61 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2002 | 78 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2002 | 139 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 106 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2003 | 75 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2002 | 356 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 817 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 379 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 695 | 0.010 |
Why?
|
| Motor Activity | 1 | 2004 | 370 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2003 | 532 | 0.010 |
Why?
|
| Torsion Abnormality | 1 | 1998 | 10 | 0.010 |
Why?
|
| Biomarkers | 1 | 2002 | 733 | 0.010 |
Why?
|
| Accidents, Traffic | 1 | 1998 | 14 | 0.010 |
Why?
|
| Anti-Dyskinesia Agents | 1 | 1998 | 6 | 0.010 |
Why?
|
| Hypertrophy | 1 | 1998 | 20 | 0.010 |
Why?
|
| Botulinum Toxins | 1 | 1998 | 28 | 0.010 |
Why?
|
| Posture | 1 | 1998 | 72 | 0.010 |
Why?
|
| Shoulder Joint | 1 | 1998 | 605 | 0.010 |
Why?
|